Biointerfaces Institute

Redefining collaboration in the physical and life sciences

Contact Us: 734.763.7924
Email: Biointerfaces.Info@umich.edu

People

Ron Larson

George Granger Brown Professor of Chemical Engineering; Professor, Mechanical Engineering and Macromolecular Science and Engineering

Nanotechnology

The Larson Group's research interests include the structure and flow properties of viscous or elastic fluids, sometimes called “complex fluids”, which include polymers, colloids, surfactant-containing fluids, liquid crystals, and biological macromolecules such as DNA, proteins, and lipid membranes. The Group is also interested in fluid mechanics, including microfluidics and transport modeling.

Larson Lab

 

 

Somin Eunice Lee

Assistant Professor, Electrical and Computer Engineering, Biomedical Engineering

Microfluidics & Sensors

The Bioplasmonics Group focuses on advancing innovations in nanoscale-dependent properties to enable unique spatial and temporal capabilities needed for quantification in bioscience and medicine. Areas of expertise include plasmonics, nanophotonics, bionanotechnologies.

Lee Lab

 

 

Scott Lempka

Assistant Professor, Biomedical Engineering

Microfluidics & Sensors

Scott Lempka’s Neuromodulation Lab uses computational models combined with experimental measurements to characterize clinical neurostimulation therapies for chronic pain management. Particular research areas include spinal cord stimulation and deep brain stimulation.

Lempka Lab

 

 

Isabelle Lombaert

Assistant Professor, Biologic & Materials Sciences, School of Dentistry

Cell & Tissue Engineering

Research in the Lombaert lab is focused on the regeneration of radiated tissues by stem cell-based therapies. In order to drive this therapeutic concept successfully, we investigate molecular and cellular research aspects during organ development, as well as in adult homeostatic and damaged conditions.

Lombaert Lab

 

 

James Moon

John Gideon Searle Assistant Professor of Pharmaceutical Sciences and Biomedical Engineering

Biomaterials & Drug Delivery

The Moon Group develops therapeutics and diagnostics at the interface of immunology and engineering. Research addresses drug delivery systems for enhancing delivery of antigen and adjuvant to lymphoid organs and manipulating immune functions in the context of cancer, infectious diseases, and autoimmunity. Current projects include design of biomaterials to recruit and expand cytotoxic CD8 T cells for eradication of metastatic tumors and prevention of HIV infection.

Moon Lab

 

 

Lisa Moran

Administrative Assistant

Administrative Team

 

 

Deepak Nagrath

Associate Professor, Biomedical Engineering

Cell & Tissue Engineering

The Nagrath lab focuses on both experimental and theoretical aspects of Cellular and Molecular Tissue Engineering, Metabolic Engineering, and Biomedicine with emphasis on clinical applications. Our research interests lie in the systems biology of metabolic diseases, specifically cancer.

Nagrath Lab

 

 

Sunitha Nagrath

Associate Professor, Chemical Engineering

Microfluidics & Sensors

The Nagrath lab research focus is on developing integrated nano and microfluidic technologies for understanding cell trafficking in cancer through isolation, characterization, and the study of circulating tumor cells in peripheral blood of cancer patients. Expertise in the Nagrath Group includes BioMEMS, microfluidics, microfabrication, cancer diagnostics, cell and tissue engineering, computational fluid dynamics, bio-fluid mechanics, and blood-on-a-chip techniques for cell sorting and cancer detection.

Nagrath Lab

 

 

Anna Schwendeman

Assistant Professor, Pharmaceutical Sciences, College of Pharmacy

Nanotechnology

Schwenedeman's principal research interest is to understand how phospholipid composition of high-density lipoprotein (HDL) affects its potency and to design short synthetic peptides that mimic various functions of Apolipoprotein A-I, the main HDL protein. Laboratory work focuses on HDL for treatment of sepsis, Alzheimer's disease, complications of diabetes, lupus and other autoimmune diseases and using synthetic HDL nanoparticles for targeted drug delivery purposes and designing artificial HDL based on gold nanoparticles. Long-term research goal includes the design of highly potent synthetic HDL nanoparticles to treat atherosclerosis.

Schwendeman Lab

 

 

Steven Schwendeman

Ara G. Paul Professor and Chair, Department of Pharmaceutical Sciences Biointerfaces Institute - Executive Committee

Biomaterials & Drug Delivery

The Schwendeman Group develops advanced polymer-based controlled drug delivery approaches, including: physical chemistry of poly(lactic-co-glycolic acid) (PLGA) and related polymers; aqueous-based encapsulation of biomacromolecules in PLGAs, mechanisms of polymer healing and drug-polymer interactions; mechanisms of instability of small and large molecules in PLGAs particularly proteins and peptides; vaccine delivery from PLGAs; PLGA nanoparticle formulation; and development of mucoadhesive polymers/formulations for intraoral and intranasal delivery.  These drug delivery strategies are most often applied to important therapeutic targets, e.g., angiogenesis in cardiovascular disease, anti-angiogenesis for macular degeneration, bone regeneration, anti-cancer therapies, and diabetes. 

Schwendeman Lab

 

 

Pages